{"id":"W2169923083","doi":"10.1200/jco.2014.55.3628","title":"Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":472,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; Children’s Oncology Group","keywords":"Gemtuzumab ozogamicin; Medicine; Hazard ratio; Internal medicine; Chemotherapy; Induction chemotherapy; Randomized controlled trial; Calicheamicin; Myeloid leukemia; Oncology; Confidence interval; CD33","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03040837,0.0005033675,0.004731571,0.0002824103,0.0001944137,0.00004932956,0.001080164,0.001210347,0.00002111917],"category_scores_gemma":[0.03483787,0.0002938317,0.000724497,0.0003636939,0.001420135,0.0002496355,0.0004546468,0.006117148,0.000007232105],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001878413,"about_ca_system_score_gemma":0.00532069,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003975934,"about_ca_topic_score_gemma":0.0005699129,"domain_scores_codex":[0.9836039,0.008410789,0.005220698,0.0008478055,0.0009931435,0.0009236983],"domain_scores_gemma":[0.9791607,0.01406898,0.004541187,0.0009907273,0.0003681628,0.0008702461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8850654,0.002145953,0.01519838,0.000006923554,0.001935075,0.00029084,0.0003343009,0.00001940579,0.0008496751,0.0000174719,0.006423396,0.08771323],"study_design_scores_gemma":[0.8606508,0.03038516,0.1028652,0.0003293573,0.002118804,0.001014956,0.0001103301,0.0008246987,0.00009368915,0.0002794678,0.001058321,0.0002692472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877671,0.0004362515,0.0008419689,0.007205451,0.0009147219,0.002413624,0.0001403425,0.0000267364,0.0002537748],"genre_scores_gemma":[0.986454,0.004420017,0.003324318,0.001589259,0.00388046,0.00002824695,0.0001062125,0.00007517614,0.0001223134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08766678,"threshold_uncertainty_score":0.9999514,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02256369829522603,"score_gpt":0.3769498515563637,"score_spread":0.3543861532611377,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}